Journal of Shanghai Jiao Tong University (Medical Science) >
A dormant cancer mouse model established by combining preimmune strategy with mVenus-p27K - system
Received date: 2024-04-28
Accepted date: 2024-08-21
Online published: 2024-09-28
Supported by
National Natural Science Foundation of China(82203228);Science and Technology Innovation Action Plan of Shanghai Municipal Science and Technology Commission(22YF1445600);“Two-hundred Talents” Program of Shanghai Jiao Tong University School of Medicine(20181708)
Objective ·To establish a mouse model with dormant cancer and no obvious metastasis by combining the preimmune strategy with the mVenus-p27K- cell G0 phase indicator system, the DTR-HSV/TK suicide gene system, and the Luc2-tdTomato tracer system. Methods ·The KPC1199 mouse pancreatic cancer cell line was transfected with the mVenus-p27K- cell G0 phase indicator system, the DTR-HSV/TK suicide gene system, and the Luc2-tdTomato tracer system to construct a stable expression cell line, KPC1199-PDL. After being cultured in the serum-free condition, KPC1199-PDL cells were sorted into mVenus (+) cells and mVenus (-) cells by flow cytometry, and the expression of G0 phase-related genes was verified by real-time fluorescence quantitative PCR (qPCR). Sensitivity of KPC1199-PDL cells to diphtheria toxin (DTX) and ganciclovir (GCV) was evaluated by CCK-8 assay. A transsplenic portal vein-hepatic metastasis model was constructed in wild-type C57BL/6 mice to validate the function of KPC1199-PDL cells in vivo by immunofluorescence technology. The KPC1199-PDL cells were injected subcutaneously into C57BL/6 mice, followed by in situ injection of DTX and GCV to ablate subcutaneous tumors 5 d later, to obtain preimmunized mice. The transsplenic portal vein-hepatic metastasis models were constructed in these mice. Bioluminescence imaging was used to evaluate subcutaneous tumor ablation and hepatic metastasis in the mice, and immunofluorescence assay was used to detect the distribution and dormant state of tumor cells in the livers of preimmunize mice. Results ·The three tool systems were stably expressed in KPC1199-PDL cells, and their proliferative ability was not affected. In the serum starving condition, some KPC1199-PDL cells expressed the mVenus protein, indicating entry into the G0 phase; the mVenus (+) cells sorted out by flow cytometry exhibited significantly higher expression of G0 phase-related genes (all P<0.05) and significantly lower expression of the proliferation-related gene compared with mVenus (-) cells (P<0.05). The CCK-8 assay demonstrated high sensitivity of KPC1199-PDL cells to DTX and GCV. In vivo experiments confirmed that KPC1199-PDL cells could be effectively traced through tdTomato protein expression, and could indicate entry into the G0 phase through mVenus protein expression. Following subcutaneous tumor implantation and drug ablation, preimmunized mice were successfully obtained. In the subsequent transsplenic portal vein-hepatic metastasis model, no metastatic signals were observed in the liver by bioluminescence imaging, but single or small clusters of G0 phase tumor cells expressing both mVenus and tdTomato, not expressing the proliferation marker Ki67, were detected in liver tissue sections by immunofluorescence analysis. Conclusions ·A recognizable and traceable dormant cancer model is constructed with the combination of the preimmune mouse model of pancreatic cancer, the mVeneus-p27K- indicator system, the DTR-HSV/TK suicide gene system, and the Luc2-tdTomato tracer system.
Musitaba MUTAILIFU , Junjie WANG , Yunzhen QIAN , Suyuan CHEN , Da SHAO , Zhigang ZHANG , Dongxue LI . A dormant cancer mouse model established by combining preimmune strategy with mVenus-p27K - system[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(9) : 1104 -1114 . DOI: 10.3969/j.issn.1674-8115.2024.09.005
1 | KLEIN A P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502. |
2 | PEREIRA S P, OLDFIELD L, NEY A, et al. Early detection of pancreatic cancer[J]. Lancet Gastroenterol Hepatol, 2020, 5(7): 698-710. |
3 | SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. |
4 | FERRONE C R, BRENNAN M F, GONEN M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors[J]. J Gastrointest Surg, 2008, 12(4): 701-706. |
5 | FERRONE C R, PIERETTI-VANMARCKE R, BLOOM J P, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure[J]. Surgery, 2012, 152(3 Suppl 1): S43-S49. |
6 | HE J, AHUJA N, MAKARY M A, et al. 2 564 resected periampullary adenocarcinomas at a single institution: trends over three decades[J]. HPB, 2014, 16(1): 83-90. |
7 | KATZ M H, WANG H M, FLEMING J B, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma[J]. Ann Surg Oncol, 2009, 16(4): 836-847. |
8 | RHIM A D, MIREK E T, AIELLO N M, et al. EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148(1/2): 349-361. |
9 | GHAJAR C M. Metastasis prevention by targeting the dormant niche[J]. Nat Rev Cancer, 2015, 15(4): 238-247. |
10 | MASSAGUé J, GANESH K. Metastasis-initiating cells and ecosystems[J]. Cancer Discov, 2021, 11(4): 971-994. |
11 | ALBRENGUES J, SHIELDS M A, NG D, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice[J]. Science, 2018, 361(6409): eaao4227. |
12 | AGUIRRE-GHISO J A. Models, mechanisms and clinical evidence for cancer dormancy[J]. Nat Rev Cancer, 2007, 7(11): 834-846. |
13 | POMMIER A, ANAPARTHY N, MEMOS N, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases[J]. Science, 2018, 360(6394): eaao4908. |
14 | MALLADI S, MACALINAO D G, JIN X, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT[J]. Cell, 2016, 165(1): 45-60. |
15 | PANTEL K, SCHLIMOK G, KUTTER D, et al. Frequent down-regulation of major histocompatibility class Ⅰ antigen expression on individual micrometastatic carcinoma cells[J]. Cancer Res, 1991, 51(17): 4712-4715. |
16 | BALDOMINOS P, BARBERA-MOURELLE A, BARREIRO O, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche[J]. Cell, 2022, 185(10): 1694-1708.e19. |
17 | HU J, SáNCHEZ-RIVERA F J, WANG Z H, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma[J]. Nature, 2023, 616(7958): 806-813. |
18 | CONNOR A A, DENROCHE R E, JANG G H, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma[J]. JAMA Oncol, 2017, 3(6): 774-783. |
19 | FEIG C, JONES J O, KRAMAN M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer[J]. Proc Natl Acad Sci U S A, 2013, 110(50): 20212-20217. |
20 | OKI T, NISHIMURA K, KITAURA J, et al. A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0-G1 transition[J]. Sci Rep, 2014, 4: 4012. |
21 | POSCHKE I, FARYNA M, BERGMANN F, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma[J]. Oncoimmunology, 2016, 5(12): e1240859. |
22 | SAUVAGEAU M, SAUVAGEAU G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer[J]. Cell Stem Cell, 2010, 7(3): 299-313. |
23 | RUBSAM L Z, BOUCHER P D, MURPHY P J, et al. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells[J]. Cancer Res, 1999, 59(3): 669-675. |
24 | PROPPER D J, BALKWILL F R. Harnessing cytokines and chemokines for cancer therapy[J]. Nat Rev Clin Oncol, 2022, 19(4): 237-253. |
25 | VESELY M D, ZHANG T X, CHEN L P. Resistance mechanisms to anti-PD cancer immunotherapy[J]. Annu Rev Immunol, 2022, 40: 45-74. |
26 | SAXENA M, VAN DER BURG S H, MELIEF C J M, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378. |
27 | SHALHOUT S Z, MILLER D M, EMERICK K S, et al. Therapy with oncolytic viruses: progress and challenges[J]. Nat Rev Clin Oncol, 2023, 20(3): 160-177. |
28 | YEH A C, RAMASWAMY S. Mechanisms of cancer cell dormancy: another hallmark of cancer?[J]. Cancer Res, 2015, 75(23): 5014-5022. |
29 | GERSTBERGER S, JIANG Q W, GANESH K. Metastasis[J]. Cell, 2023, 186(8): 1564-1579. |
30 | PHAN T G, CROUCHER P I. The dormant cancer cell life cycle[J]. Nat Rev Cancer, 2020, 20(7): 398-411. |
31 | MIN H Y, LEE H Y. Cellular dormancy in cancer: mechanisms and potential targeting strategies[J]. Cancer Res Treat, 2023, 55(3): 720-736. |
/
〈 |
|
〉 |